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Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free sur-
vival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis
of mature overall survival (OS) data.
Patients and methods: LUX-Lung 7 assessed afatinib 40mg/day versus gefitinib 250mg/day in treatment-naı¨ve pa-
tients with stage IIIb/IV NSCLC and a common EGFR mutation (exon 19 deletion/L858R). Primary OS analysis was
planned after 213 OS events and32-month follow-up. OS was analysed by a Cox proportional hazards model, strati-
fied by EGFR mutation type and baseline brain metastases.
Results: Two-hundred and twenty-six OS events had occurred at the data cut-off (8 April 2016). After a median follow-
up of 42.6 months, median OS (afatinib versus gefitinib) was 27.9 versus 24.5 months [hazard ratio (HR) ¼ 0.86, 95%
confidence interval (CI) 0.66–1.12, P¼ 0.2580]. Prespecified subgroup analyses showed similar OS trends (afatinib ver-
sus gefitinib) in patients with exon 19 deletion (30.7 versus 26.4 months; HR, 0.83, 95% CI 0.58–1.17, P¼0.2841) and
L858R (25.0 versus 21.2 months; HR 0.91, 95% CI 0.62–1.36, P¼0.6585) mutations. Most patients (afatinib, 72.6%;
gefitinib, 76.8%) had at least one subsequent systemic anti-cancer treatment following discontinuation of afatinib/gefiti-
nib; 20 (13.7%) and 23 (15.2%) patients received a third-generation EGFR tyrosine kinase inhibitor. Updated PFS
(independent review), TTF and ORR data were significantly improved with afatinib.
Conclusion: In LUX-Lung 7, there was no significant difference in OS with afatinib versus gefitinib. Updated PFS
(independent review), TTF and ORR data were significantly improved with afatinib.
Clinicaltrials.gov identifier: NCT01466660.
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introduction
Non-small-cell lung cancers (NSCLCs) with activating epider-
mal growth factor receptor (EGFR) mutations are extremely sen-
sitive to the EGFR-targeting tyrosine kinase inhibitors (TKIs)
gefitinib, erlotinib and afatinib [1–8]. These three agents are
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established first-line treatment options in this setting; however,
until recently, there was an absence of prospective randomised
head-to-head comparisons to help guide treatment decisions.
To our knowledge, the recent randomised phase IIb LUX-
Lung 7 trial was the first study to compare the irreversible ErbB
family blocker, afatinib, with a reversible EGFR TKI, gefitinib, in
treatment-naı¨ve patients with advanced NSCLC harbouring a
common EGFR mutation (exon 19 deletion/L858R) [9]. In this
trial, afatinib significantly improved progression-free survival
[PFS; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.57–
0.95, P¼ 0.0165], time-to-treatment failure (TTF; HR 0.73, 95%
CI 0.58–0.92, P¼ 0.0073) and objective response rate (ORR; 70%
versus 56%; odds ratio 1.873, 95% CI 1.176–2.985, P¼ 0.0083)
compared with gefitinib. Overall, afatinib was well tolerated,
with a predictable and manageable adverse event (AE) profile.
Treatment-related AEs were experienced in 97.5% and 96.2% of
patients in the afatinib and gefitinib arms, respectively. The most
frequent grade3 treatment-related AEs were diarrhoea
(12.5%), rash/acne (9.4%) and fatigue (5.6%) with afatinib and
elevated liver enzymes (8.8%), rash/acne (3.1%) and interstitial
lung disease (ILD) (1.9%) with gefitinib. There was one drug-
related fatal AE; a case of hepatic and renal failure with gefitinib
treatment. There was no difference in the drug discontinuation
rate due to treatment-related AEs between afatinib and gefitinib.
Along with PFS and TTF, overall survival (OS) was a co-
primary endpoint of LUX-Lung 7; however, OS data were imma-
ture at the time of the primary analysis. Here, we report the ma-
ture OS results, including prespecified subgroup analysis and
post-hoc analysis of the impact of post-study treatment on OS.
methods
study design and treatment
Full details on the trial design of LUX-Lung 7 have been published [9]. LUX-
Lung 7 was a multicentre, international, randomised, open-label phase IIb
trial (64 sites; 13 countries). Eligible patients were aged18 years with treat-
ment-naı¨ve pathologically confirmed stage IIIB/IV adenocarcinoma and a
documented common activating EGFR mutation (exon 19 deletion/L858R).
Patients had an Eastern Cooperative Oncology Group performance status
(ECOG PS) of 0 or 1, at least one measurable lesion [Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1] and adequate organ func-
tion. Patients were randomised 1:1 to once-daily oral afatinib 40mg or gefiti-
nib 250mg and were treated until disease progression, intolerable AEs
or other reasons necessitating withdrawal. Treatment beyond radiological
progression was allowed for patients deemed to be receiving continued clin-
ical benefit by the treating physician.
The co-primary endpoints were PFS by independent central review, TTF
(time from randomisation to the time of treatment discontinuation for any
reason including disease progression, treatment toxicity, and death) and OS.
ORR by independent central review was a secondary endpoint. AEs were as-
sessed according to National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0 (NCI CTCAE 3.0). Post-study treat-
ments were provided at the physician’s discretion and assessed
retrospectively.
The study was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice guidelines as defined by
the International Conference on Harmonization. All patients provided writ-
ten informed consent.
statistical plan
Three analysis timepoints were planned. The primary PFS/TTF analysis was
planned after 250 PFS events and was previously published [9]. The primary
OS analysis (reported herein) was planned after approximately 213 OS events
and a follow-up period of at least 32 months for patients still alive. The final
analysis will be undertaken at study completion (when all patients have com-
pleted treatment, or 5 years since the last patient was entered, whichever
occurs first).
All randomised patients were included in the primary assessment of OS,
and updated analysis of PFS and TTF (intention-to-treat population). Safety
analysis included all patients who received at least one dose of study drug. OS
and PFS/TTF were analysed by a log-rank test stratified by EGFR mutation
type and the presence of baseline brain metastases. A Cox proportional haz-
ards model was used to calculate HRs and 95% CIs. Prespecified subgroups
included EGFRmutation type (exon 19 deletion/L858R), baseline brainmeta-
stases (presence versus absence), ECOG PS (0 versus 1), sex, age (<65 ver-
sus65 years), ethnic origin (Asian versus non-Asian) and smoking history.
ORR and disease control rate (DCR) were compared with a logistic regression
model. All statistical testing was two sided at the nominal 5% significance
level, with no adjustment for multiplicity. Data were analysed with SAS ver-
sion 9.4.
results
patients
A total of 319 patients were randomised and treated with afatinib
(n¼ 160) or gefitinib (n¼ 159). Baseline characteristics have
been published and were similar between treatment groups [9].
Two-hundred and twenty-six OS events had occurred at the data
cut-off of 8 April 2016; 109 (68.1%) and 117 (73.6%) patients
treated with afatinib and gefitinib, respectively, had died by this
time. At the time of analysis, the median duration of treatment
was 13.7 months (range: 0–46.4) with afatinib and 11.5 months
(range: 0.5–48.7) with gefitinib. Forty (25.0%) and 21 (13.2%)
patients were treated for>24 months with afatinib and gefitinib,
respectively. At data cut-off, 14 (8.8%) and 8 (5.0%) patients re-
mained on treatment with afatinib and gefitinib.
Following discontinuation of study treatment, the majority of
patients received at least one systematic anti-cancer therapy
(72.6% and 76.8% in the afatinib and gefitinib arms, respectively;
Table 1). Many patients also received third-line (43.8% and
55.0%), fourth-line (24.0% and 31.1%) and fifth-line therapies
(13.0% and 19.2%, respectively). Fewer patients in the afatinib
arm received a subsequent EGFR TKI than in the gefitinib arm
(45.9% versus 55.6%); this imbalance was observed in both the
EGFR exon 19 deletion (51.8% versus 59.8%) and L858R (38.1%
versus 50.0%) subgroups. Twenty (13.7%) and 23 (15.2%) pa-
tients who discontinued study treatment in the afatinib and gefi-
tinib arms received a third-generation EGFR TKI.
overall survival
After a median follow-up of 42.6 months, median OS with afati-
nib versus gefitinib was 27.9 versus 24.5 months (HR, 0.86; 95%
CI 0.66–1.12; P¼ 0.2580; Figure 1A).
OS with afatinib versus gefitinib was similar across prespeci-
fied subgroups of interest (Figure 1B). There was no significant
OS difference between afatinib and gefitinib in pre-planned
subgroups that were used as stratification factors, i.e. baseline
brain metastases (presence versus absence) and EGFR
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mutation type (exon 19 deletion versus L858R). Median OS
with afatinib versus gefitinib in patients with exon 19 deletions
(30.7 versus 26.4 months; HR 0.83, 95% CI 0.58–1.17,
P¼ 0.2841; Figure 2A) and patients with the L858R mutation
(25.0 versus 21.2 months; HR 0.91, 95% CI 0.62–1.36,
P¼ 0.6585; Figure 2B) was generally consistent with the overall
EGFR mutation-positive study population. There was no inter-
action between OS and patient subgroups, except for age based on
the cut-offs of<65 and65 years (Figure 1B). However, further
post-hoc analysis demonstrated a consistent trend for OS benefit
with afatinib independent of age group (no interaction observed
at cut-offs of 60, 70 or 75 years). Similar median OS with afatinib
was seen at cut-offs of 60, 65, 70 and 75 years (supplementary
Figure S1, available at Annals of Oncology online). Of note, sub-
group sample sizes decreased with increasing age cut-off.
In a post-hoc analysis, median OS with afatinib versus gefitinib
in patients who received a third-generation EGFR TKI following
discontinuation of study treatment was ‘not evaluable’ versus
46.0 months (HR 0.51, 95%CI 0.17–1.52, P¼ 0.22; Figure 3).
other efficacy endpoints
Updated analysis of the co-primary endpoints showed similar
findings to the primary analysis [9]. PFS by independent review
(median 11.0 versus 10.9 months; HR 0.74, 95% CI 0.57–0.95,
P¼ 0.0178; supplementary Figure S2, available at Annals of
Oncology online) and TTF (median 13.7 versus 11.5 months; HR
0.75, 95% CI 0.60–0.94, P¼ 0.0136; supplementary Figure S3,
available at Annals of Oncology online) were significantly im-
proved with afatinib versus gefitinib.
Updated ORR was also significantly higher with afatinib than
with gefitinib [72.5% versus 56.0%; odds ratio 2.121 (95% CI
1.32–3.40); P¼ 0.0018; supplementary Table S1, available at
Annals of Oncology online]. The DCR was 91.3% versus 87.4%
(afatinib versus gefitinib; odds ratio 1.552, 95% CI 0.75–3.22,
P¼ 0.2372).
safety
The safety profiles of afatinib and gefitinib were virtually un-
changed since the primary analysis [9]. The frequency of all-
cause grade3 AEs was 56.9% and 53.5%, and of treatment-
related grade3 AEs was 31.3% and 19.5%, with afatinib
and gefitinib, respectively (supplementary Table S2, available
at Annals of Oncology online). The most frequent treatment-
related grade3 AEs with afatinib were diarrhoea (13.1%
versus 1.3%), rash/acne (9.4% versus 3.1%) and fatigue (5.6%
versus 0%). The most frequent treatment-related grade3
AEs with gefitinib were elevated alanine transaminase (8.2%
versus 0%), rash/acne, elevated aspartate aminotransferase (2.5%
versus 0%) and interstitial lung disease (1.9% versus 0%;
supplementary Table S2, available at Annals of Oncology
online). There was one drug-related fatal AE; a case of hep-
atic and renal failure with gefitinib treatment. Rates of treat-
ment discontinuations due to drug-related AEs remained
equally low (6.3% each).
discussion
In this updated analysis of LUX-Lung 7, a 14% reduction in risk
of death was observed in patients with EGFR mutation-positive
Table 1. Subsequent therapies in patients who discontinued study treatment, in the overall population and in EGFR mutation subgroups
Treatment, n (%) Overall population Exon 19 deletion L858R mutation
Afatinib
(n ¼ 146)
Gefitinib
(n ¼ 151)
Afatinib
(n ¼ 83)
Gefitinib
(n ¼ 87)
Afatinib
(n ¼ 63)
Gefitinib
(n ¼ 64)
None 38 (26.0) 28 (18.5) 20 (24.1) 14 (16.1) 18 (28.6) 14 (21.9)
Systemic anti-cancer therapy 106 (72.6) 116 (76.8) 61 (73.5) 69 (79.3) 45 (71.4) 47 (73.4)
Chemotherapya 84 (57.5) 91 (60.3) 48 (57.8) 55 (63.2) 36 (57.1) 36 (56.3)
Platinum based 70 (47.9) 71 (47.0) 40 (48.2) 44 (50.6) 30 (47.6) 27 (42.2)
EGFR TKI 67 (45.9) 84 (55.6) 43 (51.8) 52 (59.8) 24 (38.1) 32 (50.0)
EGFR TKI monotherapy 63 (43.2) 74 (49.0) 39 (47.0) 47 (54.0) 24 (38.1) 27 (42.2)
First-generation
Geﬁtinib 22 (15.1) 27 (17.9) 11 (13.3) 21 (24.1) 11 (17.5) 6 (9.4)
Erlotinib 23 (15.8) 30 (19.9) 16 (19.3) 21 (24.1) 7 (11.1) 9 (14.1)
Second-generation
Afatinib 6 (4.1) 12 (7.9) 4 (4.8) 8 (9.2) 2 (3.2) 4 (6.3)
Poziotinib 0 (0.0) 4 (2.6) 0 (0.0) 1 (1.1) 0 (0.0) 3 (4.7)
Third-generation
Osimertinib 15 (10.3) 17 (11.3) 9 (10.8) 11 (12.6) 6 (9.5) 6 (9.4)
Olmutinib 5 (3.4) 5 (3.3) 5 (6.0) 3 (3.4) 0 (0.0) 2 (3.1)
EGFR TKI-containing combinationb 7 (4.8) 15 (9.9) 5 (6.0) 8 (9.2) 2 (3.2) 7 (10.9)
Immune checkpoint inhibitor 3 (2.1) 4 (2.6) 2 (2.4) 4 (4.6) 1 (1.6) 0 (0.0)
Radiotherapy 26 (17.8) 34 (22.5) 16 (19.3) 15 (17.2) 10 (15.9) 19 (29.7)
aChemotherapy or chemotherapy-based combination.
bIncluding geﬁtinib (afatinib arm, n¼ 7; geﬁtinib arm, n¼ 11), erlotinib (n¼ 0; n¼ 5) and osimertinib (n¼ 0; n¼ 1).
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
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NSCLC treated with first-line afatinib versus gefitinib, that cor-
responded to a numerical difference of 3.4 months in median
OS, without reaching statistical significance. These findings were
generally consistent across key patient subgroups, including
those based on gender, ethnicity (Asian versus non-Asian), and
EGFRmutation type (exon 19 deletion versus L858R). Although
initial analyses suggested a potential interaction between OS and
patient age, subsequent post-hoc analysis demonstrated no clear
pattern of association, and similar median OS with afatinib was
observed for patients aged</60,</65,</70 and</75
years. Afatinib conferred long-term survival in a high proportion
of patients, with 24-month and 30-month survival rates of 60.9%
and 48.0%, respectively. These frequencies were consistent with
a previous global, phase III trial, which assessed afatinib versus
cisplatin/pemetrexed in patients with NSCLC harbouring com-
mon EGFR mutations (LUX-Lung 3). In this study, 59.6% and
49.8% of afatinib-treated patients survived for at least 24 and 30
months, respectively [10]. In the present study, as in the primary
analysis, afatinib significantly improved PFS, TTF and ORR ver-
sus gefitinib. No unexpected AEs were observed and discontinu-
ation rates due to treatment-related AEs remained equally low in
both arms.
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Figure 1. Overall survival. Kaplan–Meier curve (A) and forest plot of pre-speciﬁed subgroup analyses (B).
CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio.
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Despite being recognised as the first-line standard-of-care in
patients with EGFR mutation-positive NSCLC, an enduring fea-
ture of randomised controlled trials of EGFR TKIs in this setting
has been a lack of clear OS benefit, even against platinum-
doublet chemotherapy. Across multiple phase III trials, neither
erlotinib [4, 7, 11] nor gefitinib [12–14] has demonstrated statis-
tically significant OS improvement against chemotherapy.
Although afatinib did not significantly improve OS versus
chemotherapy in the overall populations of the LUX-Lung 3 and
LUX-Lung 6 trials, a significant improvement in OS was
observed with afatinib in a prespecified sub-analysis of each trial,
in patients with NSCLC harbouring exon 19 deletion mutations
[10]. In the current study, there was no significant difference in
OS between afatinib and gefitinib in patients with NSCLC har-
bouring an exon 19 deletion. Emerging evidence suggests that
first-generation and second-generation EGFR TKIs may be par-
ticularly active in NSCLC with exon 19 deletions compared with
the L858R mutation [15], but this is based on trials that used
chemotherapy as a comparator rather than TKI versus TKI com-
parisons. Therefore, as any efficacy benefit with afatinib over
gefitinib in LUX-Lung 7 would not necessarily be restricted to
patients harbouring exon 19 deletions only, we claim that the
choice of a TKI for an individual patient might not be based on
EGFRmutational profile.
The rates of post-progression therapy observed in this trial
were noticeably high. Around 75% of patients in both arms
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Figure 2. Overall survival in patients with common EGFR mutations. Patients with exon 19 deletion (A) and patients with L858R mutation (B).
CI, conﬁdence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.
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received at least one systemic anti-cancer therapy, and multiple
lines of therapy were common (25% received at least four
lines). This rate of post-progression therapy is somewhat higher
than reported in most previous trials including EGFRmutation-
positive patients treated with EGFR TKIs (66%–68% in
erlotinib trials [4, 7, 11], 64%–90% in gefitinib trials [12, 14, 16]
and 58%–70% in afatinib trials [5, 6]. In LUX-Lung 7, there were
slight imbalances in the number of patients who received a sub-
sequent first- (30.8% and 37.7%) or second-generation (4.1%
and 10.6%) EGFR TKI monotherapy in the afatinib and gefitinib
arms, respectively, although the uptake of third-generation
EGFR TKIs was similar (13.7% and 15.2%). Although there is a
general paucity of prospective data assessing the effectiveness of
sequencing of first- and second-generation EGFR TKIs, it is con-
ceivable that these imbalances might have influenced OS.
Previous studies, for example, indicate that afatinib therapy ad-
ministered post-gefitinib/erlotinib [17, 18], or gefitinib rechal-
lenge [19] offer modest efficacy benefits.
Furthermore, the limited sample size may have impaired the
power of the trial to address the differences in OS benefit be-
tween afatinib and gefitinib in clinical practice.
The primary OS analysis described herein fulfilled the proto-
col requirement in terms of the planned number of events and
minimum follow-up time. However, at the time of writing, 29%
of patients in LUX-Lung 7 were still alive and a final OS analysis
is planned on study completion to assess the impact of a reduc-
tion in censored patients. It should be noted that LUX-Lung 7
was not powered for OS. As an exploratory phase IIb trial, no for-
mal hypothesis was defined and sample size was based on con-
trolling the width of the CI for the HR of PFS [9]. Given the
influence of non-NSCLC-related deaths and post-study treat-
ments, OS requires larger sample sizes than PFS [20].
Given the recent development of third-generation EGFR TKIs
such as osimertinib and olmutinib, which are highly effective
against T790M mutation-positive tumours [21, 22], improved
understanding of, and screening for, mechanisms of acquired re-
sistance to first-line EGFR-targeted agents will allow for the
most appropriate and effective sequence of treatments for EGFR
mutation-positive NSCLC patients. It is known that 50%–60% of
patients treated with erlotinib or gefitinib develop T790M-
positive tumours following disease progression [23, 24]. Recent
data indicate a similar frequency of T790M-mediated resistance
in patients treated with first-line afatinib [25]. Therefore, regard-
less of the choice of the first-line TKI in patients with EGFR
mutation-positive NSCLC, similar numbers of patients are likely
to benefit from a subsequent third-generation EGFR TKI.
Although patient numbers are small, this assertion is supported
by the current study. In both treatment arms, survival rates were
striking in patients who received a subsequent third-generation
EGFR TKI, with 3-year OS rates of up to 90%. These findings
bode well for the strategy of sequential treatment with EGFR
TKIs, which could potentially make EGFR mutation-positive
NSCLC a chronic disease, at least in a subset of patients.
Other than the recent CTONG 0901 trial which compared gefi-
tinib with erlotinib and found no difference in efficacy and safety
[26], LUX-Lung 7 is the only published trial to compare the first-
line EGFR-targeted TKIs in patients with EGFR mutation-
positive NSCLC [although another head-to-head trial is currently
comparing the second-generation TKI, dacomitinib, versus gefiti-
nib (ARCHER-1050)]. In summary, although LUX-Lung 7 was
an exploratory phase IIb trial, we believe that the size of the trial
(with 319 randomised patients it was as large as many phase III
trials in the same setting) and the totality of the data being largely
positive across multiple clinically relevant, independently as-
sessed endpoints, suggests that afatinib may be a more effective
treatment option than gefitinib in the first-line setting.
Treatment-related AEs with afatinib were predictable, did not
negatively impact health-related quality of life, and were largely
1.0
0.8
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iva
l p
ro
ba
bi
lity
0.6
0.4 Patients subsequently treated with a third-generation EGFR TKI
0.2
0
0
Number at risk
Afatinib
Gefitinib
Afatinib (n = 20)
Gefitinib (n = 23)
HR 0.51 (95% CI 0.17–1.52)
Log-rank P = 0.22
3
20 20 20 20 20 20 20 19 19 19 19
19 19 19 15 7 4
16 13 10 8 2 0 0
0 023 23 22 22 22 21 20 20 2023
6 9 12 15 18 21 24 27
Time (months)
30 33 36 39 42 45 48 51
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manageable with tolerability-guided dose reductions such that
the treatment discontinuation rate was the same as with gefitinib.
We hypothesise that the efficacy benefits with afatinib reflect a
broader mechanism of action compared with gefitinib.
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Key Messages
In this primary analysis of overall survival (OS) data from LUX-Lung 7, there was a trend towards improved OS with afatinib versus
gefitinib in epidermal growth factor receptor mutation-positive non-small-cell lung cancer; statistical significance was not reached.
Progression-free survival (independent review), time-to-treatment failure and objective response rate significantly favoured afatinib.
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